RNA CAR T therapy Descartes‑08 targets BCMA‑positive plasma cells and delivers year‑long symptom relief in myasthenia gravis ...
While interested in CAR-T therapies’ potential to achieve durable, drug-free remission in serious autoimmune conditions, the ...
A new generation of engineered immune cell destroys cancer cells in mice 1 as effectively as conventional CAR-T-cell ...
ABC7 KABC on MSN
UCI Health launches promising clinical trial using CAR T-cell therapy to treat lupus
A promising clinical trial underway at UCI Health is aimed at helping patients achieve long-term remission.
The FDA has removed R/R PCNSL from a Limitations of Use section on the CAR-T product’s label based on positive findings from ...
Early phase 1 data suggest that in vivo, off-the-shelf CAR T therapy may be feasible in multiple myeloma, offering the promise of faster, less toxic treatment without lymphodepletion while raising ...
Lilly joins the growing list of big pharma companies hoping to see success from their acquired in vivo CAR-T programmes.
The U.S. Food & Drug Administration (FDA) recently removed its Risk Evaluation and Mitigation Strategies (REMS) designation from CAR T immunotherapies. REMS is occasionally applied to drugs with ...
ASH 2025 data on KLN-1010 suggest that off-the-shelf, in vivo CAR T therapy could significantly expand access to cellular ...
FDA officials are advising drug developers to study the long-term effects of using CAR-T in autoimmune conditions out of ...
A new study led by researchers at the UNC School of Medicine and Cartesian Therapeutics, found that immunotherapy can help ...
A first clinical study suggests allogeneic CD19-targeted CAR-T cell therapy can safely induce durable remission in patients with severe, treatment-refractory systemic lupus erythematosus.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results